Please assess the completion status of the following clinical trial:

Trial Title: Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy man between the ages of 18 and 35 years.~2. Able and willing to be located easily by providing street address and telephone number (land line and/or cell phone number).~3. Willingness to provide written informed consent.~4. Able and willing to attend all study visits including 6-day stay in the Clinical and Translational Research Center (CTRC) during the trial (with ability to leave the unit during the day) and follow-up visit during the week after treatment.~5. Able and willing to abstain from masturbation during the 6-day stay in the CTRC.~6. Able and willing to abstain from all sexual activity during the course of the study.~7. Acceptable medical history by screening evaluation.~8. Standard physical exam within normal limits (WNL).~9. Serum creatinine WNL.~10. Serum alanine transaminase (ALT) WNL.~11. White blood cell (WBC), polymorphonuclear cell (PMN) and hemoglobin values WNL.~12. Normal urinalysis.~13. Total Complement (CH50) WNL.~14. Urine negative for chlamydia, gonorrhea, trichomonas and mycoplasma.~15. Negative HIV, syphilis, and Hepatitis C (HCV) test results.~16. Negative Hepatitis B (HBV) core and surface antibodies or results consistent with immunization (negative HBV core antibody/positive HBV surface antibody).~17. Denies history of STIs including syphilis and hepatitis B \& C.~18. Denies history of bleeding diathesis.~19. Denies history of seizures (due to reports of seizures with ciprofloxacin).~20. Denies history of cancer, except basal cell carcinoma of the skin more than 5 years ago.~21. Denies history of drug abuse.~22. Denies history of psychiatric disorders, except depression controlled by medication.~23. Denies history of genitourinary surgery.~Exclusion Criteria:~1. Student or employee under the direct supervision of any of the study investigators.~2. Any known immunodeficiencies including complement deficiency, antibody deficiency, chronic granulomatous disease or HIV infection.~3. Psychiatric disorders that would interfere with the integrity of the data or volunteer safety.~4. Unstable depression (defined as receiving either \< 3 months of the same medication (and dose) or a decompensating event during the previous 3 months) or depression that, in the opinion of the investigator, will compromise the subject's ability to comply with protocol requirements.~5. Heart murmur or heart disease.~6. Anatomic abnormality of the urinary tract.~7. Any antibiotic treatment in the past 30 days, or azithromycin in the past 60 days.~8. Chemotherapy within the past year.~9. Current steroid use, except for topical application.~10. Allergy to penicillin, ceftriaxone or ciprofloxacin or to lidocaine.~11. Treatment with medications that are contraindicated with ciprofloxacin or ceftriaxone and that cannot be withheld for the single doses given in this study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Mixed FA7527/FA1090 (Type: EXPERIMENTAL): Bacterial inoculum containing a mixture of equivalent numbers of the isogenic LptA mutant and wild-type (WT) strain administered once to the anterior urethra. N= up to 25
- Mutant FA7527 (Type: EXPERIMENTAL): Bacterial inoculum containing only the isogenic LptA mutant N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8
- Wild-type FA1090 (Type: EXPERIMENTAL): Bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain administered once to the anterior urethra. N= up to 8

Based on this trial design, predict the completion outcome and termination type (if applicable).